Products & Services
News
Publications
About us
Contact
Home
innosign-logo

News

Filters
Category group 1
  • Select all
Category group 2
  • Select all
02.12.2022    SABCS 2022 events

The use of ribociclib/letrozole combination as an alternative for neoadjuvant chemotherapy

01.11.2022 news

InnoSIGN welcomes Mark Oldroyd as Board Member

05.10.2022 news

InnoSIGN aims to increase survival rates of cancer patients using PCR tests

22.09.2022 news

InnoSIGN wins Gerard & Anton Award

09.09.2022    ESMO events

High HH and low AR associated with resistance to ARDT in prostate cancer

26.07.2022 news

$9.2 M raised during Series A investment round

12.05.2022 news

InnoSIGN is developing a smart PCR test to predict which drug will work in a cancer patient

09.05.2022 news

Interview with Sr. Investment Manager BOM and CEO InnoSIGN

23.03.2022 news

PCR test predicts which medication will best work

22.03.2022 news

InnoSIGN completes spin-out from Philips, $8M Series A

15.03.2022     AACR events

Signaling pathways in high-grade serous ovarian carcinoma

  • OncoSIGNal
    • G4 PCR Test
    • G7 PCR Test
    • Service Testing
    • Data Service
  • Publications
  • About us
  • News
  • Contact

Contact us

E-Mail us oncosignal@innosignbio.com
  • Cookie Policy
  • Legal Notice
  • Privacy Policy
© 2023 InnoSIGN

Cookies

We use cookies and other technologies to personalize content, as well as to provide social media features on this Website in accordance with our Cookie Policy. By clicking “Accept” you are directing InnoSIGN to disclose your personal information to third parties for the purposes stated above.

Accept all Only functional